Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, today published a shareholder letter from CEO Brent Ness detailing strategic progress and catalysts for 2026. The letter emphasizes the company's focus on expanding adoption of its Nociscan platform, a noninvasive tool that uses biomarkers and augmented intelligence to help physicians identify pain-causing discs in the lumbar spine.
The company is actively pursuing reimbursement coverage from one or more regional insurance providers in the United States, a critical step toward broader payer adoption. In parallel, Aclarion expects an initial readout from its CLARITY clinical trial in the fourth quarter of 2026, which could provide additional clinical evidence supporting Nociscan's efficacy. The company also noted its strong balance sheet, with cash runway extending into 2028, enabling continued investment in commercialization and clinical development.
“Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business,” said Brent Ness. The company has reported increasing physician engagement and growing clinical evidence, alongside progress with payers. The full letter is available on the company's website.
Aclarion's Nociscan platform is the first evidence-supported, SaaS-based system to noninvasively distinguish painful from nonpainful discs. By analyzing magnetic resonance spectroscopy data from MRI machines, the platform quantifies chemical biomarkers associated with disc pain, providing critical insights for optimizing treatment strategies. The company believes that broader reimbursement and positive trial results will drive adoption and long-term value creation.
Forward-looking statements in the press release note that actual results may differ due to risks detailed in Aclarion's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025. The company undertakes no obligation to update forward-looking statements.
